IBIO Instantâneo da Ação
Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
Preço
$1.45
Capitalização de Mercado
$28M
P/E (TTM)
-0.8
EPS (TTM)
$-1.75
Receita (TTM)
$400.0K
Rendimento div.
—
ROE
-101.5%
Dívida/Capital
0.1
Intervalo 52 Semanas
$1 – $3
IBIO Gráfico de Preço da Ação
OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
Médias móveis e sobreposições
Volume
Osciladores
Momento e tendência
Configure
Desempenho de 10 Anos
Tendências de receita, lucro líquido, margens e EPS
Receita e Lucro Líquido$400.0K
2020-06-30→2025-06-30
EPS$-1.75
2021-06-30→2025-06-30
Fluxo de caixa livre$-15M
2021-06-30→2025-06-30
Margens-4594.2%
2021-06-30→2022-06-30
Avaliação
Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
Métrica
Tendência de 5 anos
IBIO
Mediana de Pares
P/E (TTM)
-0.8
4.7
P/S (TTM)
70.1
31.0
P/B
1.9
1.8
EV / EBITDA
-1.1
—
Price / FCF (Preço / FCF)
-1.8
—
Lucratividade
Margens bruta, operacional e líquida; ROE, ROA, ROIC
Métrica
Tendência de 5 anos
IBIO
Mediana de Pares
Operating Margin (Margem Operacional)
-4650.5%
—
Net Profit Margin (Margem de Lucro Líquido)
-4594.2%
-1601.1%
ROA
-70.8%
-68.1%
ROE
-101.5%
-111.7%
Saúde financeira
Dívida, liquidez, solvência — força do balanço patrimonial
Métrica
Tendência de 5 anos
IBIO
Mediana de Pares
Debt / Equity (Dívida / Patrimônio Líquido)
0.1
0.0
Current Ratio (Índice de liquidez corrente)
1.6
4.1
Quick Ratio (Índice de Liquidez Seca)
1.4
—
Crescimento
Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
Métrica
Tendência de 5 anos
IBIO
Mediana de Pares
Revenue YoY (Receita Ano a Ano)
77.8%
—
Revenue CAGR 3Y (CAGR Receita 3A)
-40.3%
—
Revenue CAGR 5Y (CAGR Receita 5A)
-24.6%
—
Métricas por Ação
EPS, valor patrimonial por ação, fluxo de caixa por ação, dividendo por ação
Métrica
Tendência de 5 anos
IBIO
Mediana de Pares
EPS (Diluted) (EPS (Diluído))
$-1.75
—
Eficiência de Capital
Giro de ativos, giro de estoques, giro de contas a receber
Métrica
Tendência de 5 anos
IBIO
Mediana de Pares
IBIO Consenso dos analistas
Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
COMPRA14 analistas
Compra forte
428,6%
Compra
964,3%
Manter
17,1%
Venda
00,0%
Venda forte
00,0%
Preço-alvo de 12 meses
8 analistas
· 2026-08-13
Mediana$5.00
Média$5.40
← Abaixo de todos os alvos
$1.45
Mín$4.20
Máx$7.00
Alvo mediano$5.00
+244,8%
Alvo médio$5.40
+272,4%
Histórico de Lucros
EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
Surpresa Média
-0.05%
Próximo relatório
Set 03, 2026
Período
EPS Actual
EPS est.
Surpresa
31 de Março de 2026
$-0.06
$-0.06
0.00%
31 de Dezembro de 2025
$-0.09
$-0.08
-0.01%
30 de Setembro de 2025
$-0.11
$-0.10
-0.01%
30 de Junho de 2025
$-0.49
$-0.37
-0.12%
31 de Março de 2025
$-0.49
$-0.37
-0.12%
Comparação de pares (subindústria GICS)
Métricas chave vs pares do setor
Ticker
Capitalização de Mercado
P/E
Receita YoY
Margem Líquida
ROE
Margem Bruta
IBIO
$15M
-0.4
77.8%
-4594.2%
-101.5%
—
DWTX
$124M
-0.6
123.6%
—
-83.8%
—
GOSS
$724M
-4.1
-57.7%
-351.5%
201.8%
—
CTOR
$170M
-6.0
—
—
-61.5%
—
SPRO
$131M
15.5
39.2%
12.8%
18.7%
—
CRDF
$192M
-4.1
-13.2%
-7732.0%
-88.2%
—
XBIT
—
-1.6
—
—
—
—
NMAD
—
—
—
—
—
—
MNOV
$64M
-5.5
—
-2928.8%
-27.1%
—
PMVP
$67M
-0.8
-40.5%
-1226.8%
-63.4%
—
Fundamentos Completos
Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados17
Dados anuais de Demonstração de Resultados para IBIO
Métrica
Tendência
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Revenue
$400.0K
$225.0K
$0
$2M
$2M
$2M
$2M
$444.0K
$394.0K
$948.0K
$2M
$205.0K
Cost of Revenue
·
·
·
$216.0K
$1M
$703.0K
·
·
·
·
·
·
Gross Profit
·
·
·
$2M
$909.0K
$935.0K
·
·
·
·
·
·
R&D Expense
$8M
$5M
$10M
$10M
$10M
$4M
$5M
$4M
$4M
$3M
$3M
$2M
SG&A Expense
$11M
$12M
$19M
$22M
$22M
$11M
$12M
$11M
$11M
$8M
$5M
$4M
Operating Expenses
$19M
$17M
$29M
$32M
$32M
$15M
$18M
$15M
$15M
$11M
$9M
$4M
Operating Income
$-19M
$-17M
$-29M
$-30M
$-31M
$-14M
$-16M
$-14M
$-14M
$-10M
$-7M
$-4M
Interest Expense
·
·
$83.0K
$1M
$2M
$2M
$2M
$2M
$2M
$807.0K
$0
$0
Interest Income
$437.0K
$363.0K
$213.0K
$177.0K
$140.0K
$15.0K
$75.0K
$15.0K
$39.0K
$22.0K
$9.0K
$8.0K
Other Non-op
$225.0K
$1M
$32.0K
$184.0K
$8M
$-2M
$-2M
$-2M
$-2M
$-764.0K
$41.0K
$3.0K
Income Tax
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Net Income
$-18M
$-25M
$-65M
$-50M
$-23M
$-16M
$-18M
$-16M
$-15M
$-10M
$-7M
$-4M
EPS (Basic)
$-1.75
$-6.50
$-106.19
$-5.78
$-3.00
·
·
·
·
·
·
·
EPS (Diluted)
$-1.75
$-6.50
$-106.19
$-5.78
$-3.00
·
·
·
·
·
·
·
Shares (Basic)
10,499,000
3,831,000
612,000
8,721,000
7,825,000
·
·
·
·
·
·
·
Shares (Diluted)
10,499,000
3,831,000
612,000
8,721,000
7,825,000
·
·
·
·
·
·
·
EBITDA
$-19M
$-17M
$-29M
$-50M
$-31M
·
$-16M
$-14M
$-14M
$-10M
$-7M
·
Balanço Patrimonial24
Dados anuais de Balanço Patrimonial para IBIO
Métrica
Tendência
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Cash & Equivalents
$9M
$14M
$4M
$23M
$77M
$55M
$4M
$4M
$16M
$16M
$9M
$4M
Receivables
·
$0
$0
$1M
$426.0K
$75.0K
$97.0K
$75.0K
$175.0K
$484.0K
$445.0K
$205.0K
Inventory
·
$0
$0
$4M
$27.0K
·
·
·
·
·
·
·
Prepaid Expense
$1M
$749.0K
$664.0K
$2M
$2M
$214.0K
$290.0K
$276.0K
$283.0K
$264.0K
$182.0K
$118.0K
Other Current Assets
·
·
·
·
·
·
·
·
·
·
$17.0K
$8.0K
Current Assets
$10M
$16M
$26M
$45M
$105M
$62M
$5M
$16M
$9M
$24M
$10M
$4M
PP&E (Net)
$3M
$4M
$4M
$1M
$9M
$4M
$24M
$25M
$26M
$26M
$13.0K
$6.0K
PP&E (Gross)
$5M
$5M
$5M
$1M
$10M
$4M
$29M
$28M
$27M
$26M
$40.0K
·
Accum. Depreciation
$1M
$1M
$400.0K
$0
$1M
$753.0K
$5M
$3M
$2M
$605.0K
$27.0K
·
Intangibles
$7M
$5M
$5M
$5M
$952.0K
$1M
$1M
$2M
$2M
$2M
$2M
$3M
Total Assets
$23M
$29M
$41M
$99M
$147M
$94M
$31M
$43M
$36M
$52M
$12M
$6M
Accounts Payable
$2M
$358.0K
$2M
$4M
$2M
$2M
$1M
$790.0K
$749.0K
$1M
$1M
$297.0K
Accrued Liabilities
$1M
$2M
$5M
$4M
$3M
$1M
$965.0K
$1M
$924.0K
$920.0K
$159.0K
$98.0K
Short-term Debt
$766.0K
$218.0K
$13M
$22M
$600.0K
$261.0K
$0
·
·
·
·
·
Current Liabilities
$6M
$4M
$22M
$30M
$7M
$5M
$3M
$2M
$2M
$2M
$1M
$395.0K
Capital Leases
$2M
$3M
$3M
$4M
$0
$0
$25M
$25M
$25M
$25M
$0
·
Total Liabilities
$8M
$7M
$26M
$36M
$38M
$38M
$28M
$27M
$27M
$28M
$1M
$395.0K
Total Debt
$766.0K
$218.0K
$13M
$22M
$600.0K
·
·
·
·
·
·
·
Common Stock
$19.0K
$9.0K
$1.0K
$9.0K
$9.0K
$140.0K
$20.0K
$16.0K
$9.0K
$89.0K
$77.0K
$66.0K
Retained Earnings
$-332M
$-314M
$-289M
$-224M
$-174M
$-150M
$-106M
$-88M
$-72M
$-58M
$-48M
$-41M
AOCI
·
·
·
$-213.0K
$-63.0K
$-33.0K
$-31.0K
$-30.0K
$-29.0K
$-29.0K
$-25.0K
$0
Stockholders' Equity
$15M
$21M
$15M
$63M
$109M
$57M
$2M
$16M
$9M
$10M
$11M
$6M
Liabilities + Equity
$23M
$29M
$41M
$99M
$147M
$94M
$31M
$43M
$36M
$52M
$12M
$6M
Shares Outstanding
19,349,201
8,623,676
1,015,505
8,727,158
8,714,924
140,071,110
20,152,458
16,040,126
8,911,851
89,109,410
77,205,410
65,642,095
Fluxo de Caixa12
Dados anuais de Fluxo de Caixa para IBIO
Métrica
Tendência
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
D&A
·
·
·
·
·
·
$179.0K
·
·
·
·
·
Stock-based Comp
$2M
$2M
$4M
$4M
$2M
$388.0K
$241.0K
$770.0K
$1M
$1M
$914.0K
$1M
Deferred Tax
$-9M
$-5M
$-13M
·
·
·
·
·
·
·
·
·
Amort. of Intangibles
$20.0K
$20.0K
$126.0K
$401.0K
$291.0K
$298.0K
$322.0K
$341.0K
$350.0K
$363.0K
$358.0K
$358.0K
Operating Cash Flow
$-15M
$-19M
$-30M
$-37M
$-30M
$-13M
$-14M
$-13M
$-13M
$-8M
$-5M
$-4M
CapEx
$16.0K
$210.0K
$6M
$7M
$5M
$1M
$920.0K
$934.0K
$1M
$68.0K
$13.0K
$4.0K
Investing Cash Flow
$742.0K
$906.0K
$7M
$-5M
$-26M
$-1M
$-990.0K
$-1M
$-2M
·
·
·
Stock Issued
$4M
$26M
$11M
·
·
·
·
·
$0
$6M
$10M
$480.0K
Net Stock Activity
$4M
$26M
·
·
·
·
·
·
$0
$6M
$10M
·
Financing Cash Flow
$9M
$24M
$2M
$-6M
$79M
$65M
$3M
$22M
$-170.0K
·
·
·
Net Change in Cash
$-6M
$7M
$-21M
$-49M
$22M
$51M
$-12M
$8M
$-15M
$14M
$6M
$-824.0K
Free Cash Flow
$-15M
$-19M
$-36M
$-45M
$-35M
·
$-15M
$-14M
$-14M
$-8M
$-5M
·
Lucratividade6
Dados anuais de Lucratividade para IBIO
Métrica
Tendência
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Gross Margin
·
·
·
90.9%
38.3%
·
·
·
·
·
·
·
Operating Margin
-4650.5%
-7392.9%
·
-2085.2%
-1312.1%
·
-782.4%
-3204.3%
-3622.8%
-1043.6%
-360.1%
·
Net Margin
-4594.2%
-11069.8%
·
-2110.9%
-978.8%
·
-871.8%
-3627.2%
-3688.3%
-1030.0%
-357.9%
·
EBITDA Margin
-4650.5%
-7392.9%
·
-2085.2%
-1312.1%
·
-782.4%
-3204.3%
-3622.8%
-1043.6%
-360.1%
·
ROA
-70.8%
-71.2%
-92.5%
-40.8%
-16.0%
·
-53.1%
-43.5%
-37.9%
-19.1%
-69.8%
·
ROE
-101.5%
-135.7%
-164.9%
-58.5%
-28.1%
·
-188.9%
-128.4%
-154.2%
-92.2%
-76.5%
·
Liquidez e Solvência4
Dados anuais de Liquidez e Solvência para IBIO
Métrica
Tendência
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Current Ratio
1.6
4.1
1.2
1.5
15.7
·
1.4
8.0
4.3
10.4
·
·
Quick Ratio
1.4
3.7
0.2
0.8
11.7
·
1.3
7.9
4.1
10.3
·
·
Debt / Equity
0.1
0.0
0.8
0.3
0.0
·
·
·
·
·
·
·
Interest Coverage
·
·
-353.5
-35.2
-12.7
·
-8.3
-7.4
-7.4
-12.3
·
·
Eficiência3
Dados anuais de Eficiência para IBIO
Métrica
Tendência
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Asset Turnover
0.0
0.0
0.0
0.0
0.0
·
0.1
0.0
0.0
0.0
0.2
·
Inventory Turnover
·
·
·
0.1
·
·
·
·
·
·
·
·
Receivables Turnover
·
·
·
3.3
9.5
·
23.5
3.6
1.2
2.0
5.7
·
Por Ação5
Dados anuais de Por Ação para IBIO
Métrica
Tendência
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Book Value / Share
$0.77
$2.47
$0.76
$7.27
$0.50
·
$0.12
$1.01
$0.10
$0.11
$0.15
·
Revenue / Share
$0.04
$0.06
$0.00
$0.27
·
·
·
·
·
·
·
·
Cash Flow / Share
$-1.46
$-4.84
$-2.49
$-4.30
·
·
·
·
·
·
·
·
Cash / Share
$0.44
$1.65
$0.21
$2.60
$0.36
·
$0.22
$0.99
$0.09
$0.26
$0.12
·
EPS (TTM)
$-1.75
$-6.50
$-106.19
$-5.78
$-3.00
·
·
·
·
·
·
·
Taxas de Crescimento3
Dados anuais de Taxas de Crescimento para IBIO
Métrica
Tendência
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Revenue YoY
77.8%
·
·
-20.5%
44.8%
·
·
·
·
·
·
·
Revenue CAGR 3Y
-40.3%
-54.4%
·
·
·
·
·
·
·
·
·
·
Revenue CAGR 5Y
-24.6%
·
·
·
·
·
·
·
·
·
·
·
Avaliação (TTM)14
Dados anuais de Avaliação (TTM) para IBIO
Métrica
Tendência
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Revenue TTM
$400.0K
$225.0K
$0
$2M
$2M
$2M
$2M
$444.0K
$394.0K
$948.0K
$2M
$205.0K
Net Income TTM
$-18M
$-25M
$-65M
$-50M
$-23M
$-16M
$-18M
$-16M
$-15M
$-10M
$-7M
$-4M
Market Cap
$15M
$18M
$248M
$1.13B
$164.49B
·
$7.15B
$7.22B
$173.78B
$320.79B
$366.73B
·
Enterprise Value
$7M
$4M
$256M
$1.13B
$164.42B
·
·
·
·
·
·
·
P/E
-0.4
-0.3
-0.1
-22.5
-251.7
·
·
·
·
·
·
·
P/S
36.8
80.9
·
602.2
69377.6
·
3545.2
16256.9
441068.8
338390.2
198123.0
·
P/B
1.0
0.9
16.1
17.9
1514.9
·
2904.6
446.5
19495.3
32282.8
32653.0
·
P / Tangible Book
1.8
1.1
24.8
19.3
1528.3
2802.7
·
·
·
·
·
·
P / Cash Flow
-1.0
-1.0
-8.1
-30.3
-5471.5
·
-511.9
-535.5
-13202.2
-39741.6
-77613.9
·
P / FCF
-1.0
-1.0
-6.8
-25.3
-4702.0
·
-480.3
-500.8
-11996.5
-39409.6
-77400.9
·
EV / EBITDA
-0.4
-0.3
-8.7
-22.8
-5284.9
·
·
·
·
·
·
·
EV / FCF
-0.4
-0.2
-7.1
-25.3
-4699.8
·
·
·
·
·
·
·
EV / Revenue
17.2
18.7
·
601.9
69345.2
·
·
·
·
·
·
·
Earnings Yield
-230.3%
-308.1%
-870.4%
-4.5%
-0.40%
·
·
·
·
·
·
·
Demonstração de Resultados15
Dados trimestrais de Demonstração de Resultados para IBIO
Métrica
Tendência
Q3 2026
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Q3 2023
Q2 2023
Q1 2023
Q4 2022
Revenue
$0
$0
$100.0K
$200.0K
$0
$200.0K
$0
$175.0K
$0
$0
$50.0K
$0
$0
$0
$0
$0
R&D Expense
$3M
$4M
$4M
$3M
$2M
$2M
$1M
$1M
$904.0K
$2M
$2M
$2M
$3M
$3M
$3M
$4M
SG&A Expense
$5M
$5M
$3M
$2M
$3M
$3M
$3M
$2M
$3M
$3M
$4M
$3M
$4M
$8M
$5M
$7M
Operating Expenses
$8M
$9M
$6M
$5M
$5M
$5M
$4M
$4M
$4M
$4M
$5M
$5M
$6M
$11M
$8M
$10M
Operating Income
$-8M
$-9M
$-6M
$-5M
$-5M
$-4M
$-4M
$-3M
$-4M
$-4M
$-5M
$-5M
$-6M
$-11M
$-8M
$-10M
Interest Expense
·
·
·
·
·
·
·
·
$52.0K
$34.0K
$26.0K
·
$35.0K
$31.0K
·
·
Interest Income
$657.0K
$493.0K
$267.0K
$79.0K
$72.0K
$112.0K
$174.0K
$223.0K
$43.0K
$42.0K
$55.0K
$50.0K
$23.0K
$41.0K
$99.0K
$66.0K
Other Non-op
$635.0K
$452.0K
$231.0K
$35.0K
$18.0K
$55.0K
$117.0K
$163.0K
$991.0K
$8.0K
$29.0K
$33.0K
$-110.0K
$10.0K
$99.0K
$68.0K
Income Tax
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Net Income
$-8M
$-9M
$-6M
$-5M
$-5M
$-4M
$-4M
$-8M
$-3M
$-8M
$-6M
$-6M
$-7M
$-34M
$-18M
$-17M
EPS (Basic)
$-0.06
$-0.09
$-0.11
$-0.32
$-0.49
$-0.48
$-0.46
$3.57
$-0.85
$-4.42
$-4.80
$-24.64
$-11.07
$-68.43
$-2.05
$-1.96
EPS (Diluted)
$-0.06
$-0.09
$-0.11
$-0.32
$-0.49
$-0.48
$-0.46
$3.57
$-0.85
$-4.42
$-4.80
$-24.64
$-11.07
$-68.43
$-2.05
$-0.59
Shares (Basic)
119,600,000
99,133,000
52,981,000
-17,128,000
9,862,000
9,132,000
8,633,000
-2,936,000
3,713,000
1,856,000
1,198,000
-9,379,000
659,000
490,000
8,842,000
-17,428,000
Shares (Diluted)
119,600,000
99,133,000
52,981,000
-17,128,000
9,862,000
9,132,000
8,633,000
-2,936,000
3,713,000
1,856,000
1,198,000
-9,379,000
659,000
490,000
8,842,000
-17,428,000
EBITDA
$-8M
$-9M
$-6M
·
$-5M
$-4M
$-4M
·
$-4M
$-4M
$-5M
·
$-6M
$-11M
$-8M
·
Balanço Patrimonial23
Dados trimestrais de Balanço Patrimonial para IBIO
Métrica
Tendência
Q3 2026
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Q3 2023
Q2 2023
Q1 2023
Q4 2022
Cash & Equivalents
$48M
$29M
$28M
$9M
$5M
$7M
$11M
$14M
$5M
$3M
$1M
$4M
$7M
$4M
$10M
$23M
Receivables
·
·
$65.0K
·
·
·
·
·
·
·
$0
·
$70.0K
$970.0K
$1M
$1M
Inventory
·
·
·
·
·
·
·
·
$0
$0
$0
$0
·
·
·
$4M
Prepaid Expense
$2M
$670.0K
$1M
$1M
$1M
$1M
$667.0K
$749.0K
$862.0K
$894.0K
$451.0K
$664.0K
$921.0K
$414.0K
$1M
$2M
Current Assets
$77M
$53M
$51M
$10M
$6M
$8M
$12M
$16M
$36M
$20M
$23M
$26M
$27M
$38M
$64M
$45M
PP&E (Net)
$3M
$3M
$3M
$3M
$3M
$3M
$4M
$4M
$4M
$4M
$4M
$4M
$4M
$4M
$3M
$1M
PP&E (Gross)
$5M
$5M
$5M
$5M
$5M
$5M
$5M
$5M
$5M
$5M
$5M
$5M
$5M
$4M
·
$1M
Accum. Depreciation
$2M
$2M
$2M
$1M
$1M
$1M
$1M
$1M
$893.0K
$729.0K
$565.0K
$400.0K
$235.0K
$115.0K
·
$0
Intangibles
$2M
$4M
$7M
$7M
$6M
$6M
$5M
$5M
$5M
$5M
$5M
$5M
$5M
$5M
$6M
$5M
Total Assets
$86M
$64M
$64M
$23M
$19M
$22M
$25M
$29M
$50M
$34M
$38M
$41M
$44M
$52M
$85M
$99M
Accounts Payable
$3M
$3M
$3M
$2M
$1M
$614.0K
$855.0K
$358.0K
$1M
$2M
$2M
$2M
$2M
$4M
$5M
$4M
Accrued Liabilities
$2M
$2M
$850.0K
$1M
$1M
$2M
$1M
$2M
$4M
$4M
$3M
$5M
$4M
$5M
$3M
$4M
Short-term Debt
·
·
$706.0K
$766.0K
$824.0K
$237.0K
$227.0K
$218.0K
$13M
$13M
$13M
·
$14M
$16M
$22M
$22M
Current Liabilities
$7M
$6M
$6M
$6M
$5M
$5M
$3M
$4M
$21M
$22M
$21M
$22M
$22M
$28M
$32M
$30M
Capital Leases
$2M
$2M
$2M
$2M
$2M
$2M
$3M
$3M
$3M
$3M
$3M
$3M
$3M
$3M
$3M
$4M
Total Liabilities
$8M
$8M
$8M
$8M
$8M
$8M
$7M
$7M
$25M
$25M
$24M
$26M
$27M
$33M
$36M
$36M
Total Debt
·
·
$706.0K
·
$824.0K
$237.0K
$227.0K
·
$13M
$13M
$13M
·
$14M
$16M
$22M
·
Common Stock
$35.0K
$30.0K
$20.0K
$19.0K
$10.0K
$9.0K
$9.0K
$9.0K
$9.0K
$30.0K
$28.0K
$1.0K
$16.0K
$12.0K
$9.0K
$9.0K
Retained Earnings
$-355M
$-347M
$-338M
$-332M
$-327M
$-322M
$-318M
$-314M
$-306M
$-303M
$-295M
$-289M
$-283M
$-276M
$-242M
$-224M
AOCI
$-21.0K
$10.0K
$-15.0K
·
·
·
·
·
·
·
·
·
·
$-167.0K
$-223.0K
$-213.0K
Stockholders' Equity
$78M
$57M
$56M
$15M
$11M
$14M
$18M
$21M
$25M
$9M
$13M
$15M
$17M
$19M
$48M
$63M
Liabilities + Equity
$86M
$64M
$64M
$23M
$19M
$22M
$25M
$29M
$50M
$34M
$38M
$41M
$44M
$52M
$85M
$99M
Shares Outstanding
34,543,561
30,053,070
20,254,599
19,349,201
10,066,276
9,167,670
8,637,895
8,623,676
8,517,449
3,243,725
27,653,582
1,015,505
12,368,287
12,368,287
9,006,582
8,727,158
Fluxo de Caixa10
Dados trimestrais de Fluxo de Caixa para IBIO
Métrica
Tendência
Q3 2026
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Q3 2023
Q2 2023
Q1 2023
Q4 2022
Stock-based Comp
$377.0K
$253.0K
$323.0K
$270.0K
$370.0K
$475.0K
$415.0K
$360.0K
$457.0K
$456.0K
$765.0K
$446.0K
$2M
$1M
$1M
$1M
Amort. of Intangibles
$5.0K
$5.0K
$5.0K
$5.0K
$5.0K
$5.0K
$5.0K
$5.0K
$5.0K
$5.0K
$5.0K
$5.0K
$5.0K
$49.0K
$67.0K
$68.0K
Operating Cash Flow
$-6M
$-5M
$-6M
$-5M
$-3M
$-4M
$-4M
$-5M
$-4M
$-5M
$-5M
$-5M
$-4M
$-8M
$-14M
$-12M
CapEx
$11.0K
$516.0K
$32.0K
$1.0K
$14.0K
$1.0K
$0
$210.0K
$0
·
·
$506.0K
$-201.0K
$3M
$2M
$3M
Investing Cash Flow
$-3M
$-3M
$-21M
$45.0K
$-14.0K
$-2.0K
$713.0K
$-144.0K
$1M
$0
$50.0K
$-6.0K
$8M
$-1M
$29.0K
$477.0K
Stock Issued
$3M
$0
$219.0K
$2M
$1M
$0
$4.0K
$14M
$4M
$4M
$3M
·
·
·
·
·
Net Stock Activity
·
·
$219.0K
·
·
·
$4.0K
·
·
·
·
·
·
·
·
·
Financing Cash Flow
$28M
$9M
$47M
$8M
$1M
$-152.0K
$-162.0K
$13M
$5M
$4M
$2M
$3M
$1M
$-3M
$1M
$-10.0K
Net Change in Cash
$19M
$561.0K
$20M
$4M
$-2M
$-4M
$-3M
$8M
$2M
$-701.0K
$-3M
$-2M
$6M
$-12M
$-13M
$-11M
Free Cash Flow
·
·
$-6M
·
·
·
·
·
·
·
·
·
·
·
$-16M
·
Lucratividade5
Dados trimestrais de Lucratividade para IBIO
Métrica
Tendência
Q3 2026
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Q3 2023
Q2 2023
Q1 2023
Q4 2022
Operating Margin
·
·
-5951.0%
·
·
-2209.5%
·
·
·
·
-10206.0%
·
·
·
·
·
Net Margin
·
·
-5720.0%
·
·
-2182.0%
·
·
·
·
-11492.0%
·
·
·
·
·
EBITDA Margin
·
·
-5951.0%
·
·
-2209.5%
·
·
·
·
-10206.0%
·
·
·
·
·
ROA
-14.7%
-20.9%
-12.9%
·
-14.0%
-15.7%
-12.8%
·
-6.7%
-19.1%
-9.4%
·
-9.1%
-37.6%
-15.9%
·
ROE
-17.4%
-25.5%
-15.5%
·
-26.8%
-37.8%
-25.8%
·
-15.0%
-58.6%
-18.7%
·
-15.1%
-61.3%
-24.3%
·
Liquidez e Solvência4
Dados trimestrais de Liquidez e Solvência para IBIO
Métrica
Tendência
Q3 2026
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Q3 2023
Q2 2023
Q1 2023
Q4 2022
Current Ratio
11.9
9.0
8.4
·
1.1
1.8
3.4
·
1.7
0.9
1.1
·
1.2
1.4
2.0
·
Quick Ratio
7.3
4.9
4.7
·
0.9
1.5
3.2
·
0.2
0.1
0.1
·
0.3
0.2
0.3
·
Debt / Equity
·
·
0.0
·
0.1
0.0
0.0
·
0.5
1.4
1.0
·
0.8
0.9
0.5
·
Interest Coverage
·
·
·
·
·
·
·
·
-69.7
-132.2
-196.3
·
-176.3
-341.1
·
·
Eficiência2
Dados trimestrais de Eficiência para IBIO
Métrica
Tendência
Q3 2026
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Q3 2023
Q2 2023
Q1 2023
Q4 2022
Asset Turnover
·
0.0
0.0
·
0.0
0.0
0.0
·
·
·
0.0
·
0.0
0.0
0.0
·
Receivables Turnover
·
·
3.1
·
·
·
·
·
·
·
0.1
·
0.0
0.0
0.0
·
Por Ação5
Dados trimestrais de Por Ação para IBIO
Métrica
Tendência
Q3 2026
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Q3 2023
Q2 2023
Q1 2023
Q4 2022
Book Value / Share
$2.24
$1.88
$2.77
·
$1.13
$1.52
$2.06
·
$2.92
$2.84
$0.48
·
$1.41
$1.52
$5.37
·
Revenue / Share
·
$0.00
$0.00
·
$0.00
$0.02
$0.00
·
·
·
$0.00
·
$0.00
$0.00
$0.00
·
Cash Flow / Share
·
·
$-0.11
·
·
·
$-0.43
·
·
·
$-0.22
·
·
·
$-1.58
·
Cash / Share
$1.38
$0.95
$1.39
·
$0.49
$0.77
$1.28
·
$0.62
$0.86
$0.05
·
$0.53
$0.30
$1.10
·
EPS (TTM)
$-0.75
$-1.17
$-1.54
·
$-2.28
$-6.21
$-10.53
·
$-21.14
$-88.72
$-86.35
·
$-82.97
$-73.27
$-7.24
·
Avaliação (TTM)14
Dados trimestrais de Avaliação (TTM) para IBIO
Métrica
Tendência
Q3 2026
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Q3 2023
Q2 2023
Q1 2023
Q4 2022
Revenue TTM
$300.0K
$300.0K
$300.0K
·
·
·
·
·
$50.0K
$50.0K
$50.0K
·
$2M
$2M
$2M
·
Net Income TTM
$-27M
$-24M
$-19M
·
$-16M
$-20M
$-21M
·
$-24M
$-55M
$-65M
·
$-71M
$-76M
$-51M
·
Market Cap
$66M
$58M
$17M
·
$40M
$22M
$19M
·
$35M
$4M
$166M
·
$515M
$109M
$766M
·
Enterprise Value
·
·
$-11M
·
$36M
$16M
$8M
·
$42M
$14M
$177M
·
$522M
$121M
$778M
·
P/E
-2.5
-1.6
-0.5
·
-1.8
-0.4
-0.2
·
-0.2
-0.0
-0.1
·
-0.5
-0.1
-11.7
·
P/S
218.8
193.3
56.0
·
·
·
·
·
691.6
88.9
3318.4
·
285.8
60.5
406.3
·
P/B
0.8
1.0
0.3
·
3.6
1.6
1.1
·
1.4
0.5
12.6
·
29.6
5.8
15.8
·
P / Tangible Book
0.9
1.1
0.3
·
7.7
2.9
1.5
·
1.8
1.2
21.2
·
42.9
8.1
18.1
·
P / Cash Flow
·
·
-3.0
·
·
·
-5.2
·
·
·
-31.1
·
·
·
-54.8
·
P / FCF
·
·
-3.0
·
·
·
·
·
·
·
·
·
·
·
-46.6
·
EV / EBITDA
·
·
1.8
·
-7.4
-3.5
-2.0
·
-11.6
-3.2
-34.7
·
-84.6
-11.5
-101.9
·
EV / FCF
·
·
1.9
·
·
·
·
·
·
·
·
·
·
·
-47.3
·
EV / Revenue
·
·
-35.3
·
·
·
·
·
838.7
286.2
3541.7
·
289.8
67.3
412.9
·
Earnings Yield
-39.5%
-60.6%
-185.5%
·
-56.7%
-253.5%
-474.3%
·
-520.7%
-6475.9%
-1439.2%
·
-199.4%
-832.6%
-8.5%
·
Demonstrações Financeiras
Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
Demonstração de Resultados
2025-06-30
2024-06-30
2023-06-30
2022-06-30
2021-06-30
Receita
$400.0K
$225.0K
$0
$2M
$2M
Margem Bruta %
—
—
—
90.9%
38.3%
Margem Operacional %
-4650.5%
-7392.9%
—
-2085.2%
-1312.1%
Lucro líquido
$-18M
$-25M
$-65M
$-50M
$-23M
EPS Diluído
$-1.75
$-6.50
$-106.19
$-5.78
$-3.00
Balanço Patrimonial
2025-06-30
2024-06-30
2023-06-30
2022-06-30
2021-06-30
Dívida / Patrimônio Líquido
0.1
0.0
0.8
0.3
0.0
Índice de liquidez corrente
1.6
4.1
1.2
1.5
15.7
Índice de Liquidez Seca
1.4
3.7
0.2
0.8
11.7
Fluxo de Caixa
2025-06-30
2024-06-30
2023-06-30
2022-06-30
2021-06-30
Fluxo de caixa livre
$-15M
$-19M
$-36M
$-45M
$-35M
Minhas Métricas
Sua lista pessoal — linhas selecionadas de Fundamentos Completos
📊
Escolha as métricas que importam para você — clique no ➕ ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.
Investidores institucionais (13F)
60 declarantes · $59.4M total · Em 30 de Junho de 2026
Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.
Atividade institucional — Q2 2026 vs trimestre anterior
Novas posições
Posições encerradas
Aumentou
Diminuído
Variação líquida de ações
19
(+3 vs trimestre anterior)
12
(+1 vs trimestre anterior)
18
(+4 vs trimestre anterior)
9
(+1 vs trimestre anterior)
+15.4M
Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Ativistas e proprietários de 5%+
5 participações
Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.
Declarante
Declarado
Participação
Status
Propósito
Declaração
EASTERN CAPITAL LIMITED, PORTFOLIO SERVICES LTD., KENNETH B. DART
×18 declarações
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Participação em ETFs
Detido por 3 ETFs
O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.